CRF Health Selected for Oncology Trials
The sponsors will use CRF Health's TrialMax® platform to support data capture for quality of life issues during the post-progression phase.
CRF Health, a global provider of eCOA solutions, announced it has agreements with two top tier pharmaceutical companies to support Phase III trials in ovarian and breast cancer. The sponsors will use CRF Health's TrialMax® platform to support data capture for quality of life issues during the post-progression phase. The three studies-two in breast cancer and one in ovarian--will encompass 542 sites, 23 countries and almost 2,000 female trial participants, across the U.S, Europe and Asia Pacific.
Read the full release.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
